Rare blood clot cases not higher after AstraZeneca second dose: Study

The data found that the estimated rate of thrombosis with thrombocytopenia syndrome (TTS) after the second dose of the vaccine, Vaxzevria, was 2.3 per million in those inoculated, comparable to the typical rate seen in those who have not been vaccinated, AstraZeneca said.
Source: The Economic Times - Category: Consumer Health News Source Type: news